For glioma phenotyping, IDH1/2, 1p/19q, MGMT, hTERT, TP53, PTEN, EGFR, and ATRX mutations are usually regarded as the key factors influencing postoperative therapeutic decisions, such as radiotherapy, chemotherapy, molecular targeted therapy and immune therapy (37). This evidence concerns the gene TP53 and glioma.